A risk index for early node-negative breast cancer

被引:22
作者
Boyages, J.
Taylor, R.
Chua, B.
Ung, O.
Bilous, M.
Salisbury, E.
Wilcken, N.
机构
[1] Univ Sydney, Westmead Hosp, New S Wales Breast Canc Inst, Westmead, NSW 2145, Australia
[2] Univ Sydney, Westmead Hosp, Dept Radiat Oncol, Westmead, NSW 2145, Australia
[3] Univ Sydney, Westmead Hosp, Dept Anat Pathol, Westmead, NSW 2145, Australia
[4] Univ Sydney, Westmead Hosp, Dept Med Oncol, Westmead, NSW 2145, Australia
[5] Univ Sydney, Westmead Hosp, Dept Surg, Westmead, NSW 2145, Australia
[6] Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia
关键词
D O I
10.1002/bjs.5207
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background: This study compared the application of the St Gallen 2001 classification with a risk index developed at the New South Wales Breast Cancer Institute (BCI Index) for women with node-negative breast cancer treated without adjuvant systemic therapy. Methods: The BCI risk categories were constructed by identifying combinations of prognostic indicators that produced homogeneous low-, intermediate- and high-risk groups using the same variables as in the St Gallen classification. Results: The BCI low-risk category consisted of women aged 3 5 years or more with a grade 1 oestrogen receptor (ER)-positive tumour 20 turn or less in diameter, or with a grade 2 ER-positive tumour of 15 turn or less. This category constituted 40.1 per cent of patients, with a 10-year distant relapse-free survival (DRFS) rate of 97.2 per cent. The BCI intermediate- risk category included women aged 35 years or more with a grade 2 ER-positive turnout of diameter 16-20 mm, or a grade 1 or 2 ER-negative tumour measuring 15 mm or less, and comprised 12.1 percent of the women, with a 10-year DRFS rate of 88 per cent. The high-risk category comprised 47.7 per cent of women, with a 10-year DRFS rate of 68.4 per cent. Conclusion: If confirmed in other data sets, the BCI Index may be used to identify women at low risk of distant relapse (2.8 per cent at 10 years) who are unlikely to benefit from adjuvant systemic therapy, and women at intermediate risk of distant relapse (12 per cent at 10 years) in whom the benefit of adjuvant systemic therapy is small.
引用
收藏
页码:564 / 571
页数:8
相关论文
共 22 条
[1]  
Abe O, 1998, LANCET, V352, P930
[2]   HISTOLOGICAL GRADING AND PROGNOSIS IN BREAST CANCER - A STUDY OF 1409 CASES OF WHICH 359 HAVE BEEN FOLLOWED FOR 15 YEARS [J].
BLOOM, HJG ;
RICHARDSON, WW .
BRITISH JOURNAL OF CANCER, 1957, 11 (03) :359-&
[3]   EARLY BREAST-CANCER - COSMETIC AND FUNCTIONAL RESULTS AFTER TREATMENT BY CONSERVATIVE TECHNIQUES [J].
BOYAGES, J ;
BARRACLOUGH, B ;
MIDDLEDORP, J ;
GORMAN, D ;
LANGLANDS, AO .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1988, 58 (02) :111-121
[4]   Use of the St Gallen classification for patients with node-negative breast cancer may lead to overuse of adjuvant chemotherapy [J].
Boyages, J ;
Chua, B ;
Taylor, R ;
Bilous, M ;
Salisbury, E ;
Wilcken, N ;
Ung, O .
BRITISH JOURNAL OF SURGERY, 2002, 89 (06) :789-796
[5]  
CLARK GM, 1995, ASTRO P, V14, P96
[6]  
Clarke M, 1998, LANCET, V351, P1451
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]  
FISHER B, 1970, SURG GYNECOL OBSTETR, V131, P79
[9]   THE NOTTINGHAM PROGNOSTIC INDEX IN PRIMARY BREAST-CANCER [J].
GALEA, MH ;
BLAMEY, RW ;
ELSTON, CE ;
ELLIS, IO .
BREAST CANCER RESEARCH AND TREATMENT, 1992, 22 (03) :207-219
[10]   Meeting highlights: International consensus panel on the treatment of primary breast cancer [J].
Goldhirsch, A ;
Glick, JH ;
Gelber, RD ;
Coates, AS ;
Senn, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (18) :3817-3827